BeiGene gets speedy US review for lymphoma drug zanubrutinib

First US filing is major milestone for Chinese firm. Chinese biopharma company BeiGene has claimed priority review status for its BTK inhibitor zanubrutinib from the FDA, setting up a possible approval

AstraZeneca buys FDA priority review voucher from Sobi

Picks up coveted voucher for $95m. AstraZeneca has paid Swedish biopharma company Sobi $95m in cash for an FDA priority review voucher (PRV), which could help cut four months off the

Lilly’s Levi Garraway will replace Sandra Horning as Roche CMO

The CMO job at Roche is a prestigious one, with responsibility for making the most of one of the biggest R&D budgets in the biopharma industry at more than $11bn

AZ claims first-in-class win for Farxiga in heart failure

Mene Pangalos. The company’s head of biopharma R&D, Mene Pangalos, said that at the moment “half of heart failure patients will die within five years of diagnosis and it

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]